• Explore /
  • Poster
  • / Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician’s choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Abstract Video & Slides Poster

Authors

null

Maria-Victoria Mateos

University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain

Maria-Victoria Mateos , Ajai Chari , Saad Zafar Usmani , Hartmut Goldschmidt , Katja Weisel , Keqin Qi , Anil Londhe , Sandhya Nair , Xiwu Lin , Lixia Pei , Eric Ammann , Rachel Kobos , Jennifer Smit , Trilok V. Parekh , Mary Slavcev , Philippe Moreau

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8034)

DOI

10.1200/JCO.2022.40.16_suppl.8034

Abstract #

8034

Poster Bd #

458

Abstract Disclosures

Similar Posters

First Author: Niels W.C.J. van de Donk

First Author: Philippe Moreau

First Author: Ross Firestone

First Author: Paula Rodríguez-Otero